Abstract:

Objective　Analysis of the impact of risperidone combined with transcranial magnetic stimulation on the clinical symptoms of patients with schizophrenia. Methods　A prospective study was adopted. A total of 90 patients with schizophrenia who were admitted to Ankang Central Hospital from June 2021 to December 2023 were selected. They were divided into the conventional group and the research group according to the random number table method, with 45 cases in each group.Control group: 23 males and 22 females, with an age of (40.04±4.93) years and an  disease duration of (4.24±1.12) years.Oral risperidone treatment was adopted (the dose on the first day was 1 mg per time, twice a day; the dose was increased to 3 mg per day on the third day; it was increased to 4 mg per day on the fifth day; after two weeks of adjustment, the dosage was finalized and no further changes were made). Research group: 21 males and 24 females, with an average age of (40.28±4.76) years and an average disease duration of (4.28±1.16) years. In addition to the conventional treatment, transcranial magnetic stimulation at a frequency of 10 Hz was combined.Both groups were intervened for one month.Compare the cognitive functions, clinical symptoms and therapeutic effects of the two groups before and after the intervention.Statistical methods employed were the χ² test and the t test. Results　After the intervention, the score of the Wechsler Memory Scale (WMS) in the study group was higher than that in the control group [(120.49±10.26) points vs. (115.74±10.04) points], and the score of the Positive and Negative Syndrome Scale (PANSS) was lower than that in the control group [(109.29±10.27) points vs. (115.38±10.76) points], and the differences were statistically significant (t=2.220 and 2.747; both P<0.05).After the intervention, the total effective rate of treatment in the study group was higher than that in the control group [91.11% (41/45) vs. 75.56% (34/45)], and the difference was statistically significant (t=3.920, P<0.05). Conclusion　Risperidone combined with transcranial magnetic stimulation is beneficial for promoting the recovery of cognitive function in patients with schizophrenia, alleviating related clinical symptoms, and improving clinical efficacy. It has certain promotional value.

Key words:

Risperidone, Transcranial magnetic stimulation, Schizophrenia, Cognitive function

摘要：

目的　分析利培酮联合经颅磁刺激对精神分裂症患者临床症状的影响。方法　采用前瞻性研究。选取安康市中心医院2021年6月至2023年12月收治的90例精神分裂症患者，按随机数字表法分为常规组和研究组，各45例。常规组：男23例，女22例，年龄（40.04±4.93）岁，病程（4.24±1.12）年；采取口服利培酮治疗（第1天剂量为1 mg/次，2次/d；第3天剂量加至3 mg/d；第5天加至4 mg/d；2周内调整完成后不再更改）。研究组：男21例，女24例，年龄（40.28±4.76）岁，病程（4.28±1.16）年；在常规组基础上联合频率10 Hz的经颅磁刺激治疗。两组均干预1个月。比较两组干预前后认知功能、临床症状与疗效。统计学方法采用χ²检验、t检验。结果　干预后，研究组韦氏记忆量表（WMS）量表评分高于常规组［（120.49±10.26）分比（115.74±10.04）分］，阳性与阴性症状量表（PANSS）评分低于常规组［（109.29±10.27）分比（115.38±10.76）分］，差异均有统计学意义（t=2.220、2.747，均P<0.05）。干预后，研究组治疗总有效率高于常规组［91.11%（41/45）比75.56%（34/45）］，差异有统计学意义（t=3.920，P<0.05）。结论　利培酮联合经颅磁刺激治疗有利于促进精神分裂症患者认知功能恢复，缓解相关临床症状，提高临床疗效，具有一定推广价值。

关键词:

利培酮, 经颅磁刺激, 精神分裂症, 认知功能